神経内分泌がん(Neuroendocrine Carcinoma):世界の治験レビュー(2016年上半期版)

◆英語タイトル:Neuroendocrine Carcinoma Global Clinical Trials Review, H1, 2016
◆商品コード:GDHC3215CTIDB
◆発行会社(リサーチ会社):GlobalData
◆発行日:2016年2月
◆ページ数:74
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥280,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD5,000 ⇒換算¥560,000見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD7,500 ⇒換算¥840,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界における神経内分泌がん(Neuroendocrine Carcinoma) 治療の臨床試験動向について調査・分析し、アジア太平洋/欧州/北米/中南米の主要国における治験件数、段階(フェーズ)別の治験件数、進捗状況別の治験件数、治験目標の達成状況、有望な薬剤、治験関連の最新ニュース、代表的な企業・大学・研究機関における治験概要、代表的な治験のプロファイルなどのデータをまとめてお届けいたします。

・イントロダクション
  - 神経内分泌がん(Neuroendocrine Carcinoma)
  - 当レポートの概要
・神経内分泌がん(Neuroendocrine Carcinoma):各地域別治験状況
  - 各国の治験件数及び平均被験者数
   アジア太平洋の主要国における治験件数
   欧州の主要国における治験件数
   北米の主要国における治験件数
   中東・アフリカの主要国における治験件数
   中南米の主要国における治験件数
・G7諸国での治験件数
・G7諸国での治験件数:段階別
・G7諸国での治験件数:進捗状況別
・段階(フェーズ)別の治験件数:進行中の治験(段階別)
・進捗状況別の治験件数
・治験目標の達成状況
・未完了の治験件数
・一定期間に採用された被験者
・スポンサーの種類別治験件数
・有望なスポンサー
・有望な薬剤
・治験のプロファイル
  - 代表的な企業における治験概要
  - 代表的な大学・研究機関における治験概要
・5つの代表的な治験のプロファイル
【レポートの概要】

Neuroendocrine Carcinoma Global Clinical Trials Review, H1, 2016

Summary

GlobalData’s clinical trial report, “Neuroendocrine Carcinoma Global Clinical Trials Review, H1, 2016″ provides an overview of Neuroendocrine Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Neuroendocrine Carcinoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Report Guidance 4
Clinical Trials by Region 5
Clinical Trials and Average Enrollment by Country 6
Top Countries Contributing to Clinical Trials in Asia-Pacific 8
Top Five Countries Contributing to Clinical Trials in Europe 9
Top Countries Contributing to Clinical Trials in North America 10
Top Countries Contributing to Clinical Trials in Central and South America 11
Clinical Trials by G7 Countries: Proportion of Neuroendocrine Carcinoma to Oncology Clinical Trials 12
Clinical Trials by Phase in G7 Countries 13
Clinical Trials in G7 Countries by Trial Status 14
Clinical Trials by E7 Countries: Proportion of Neuroendocrine Carcinoma to Oncology Clinical Trials 15
Clinical Trials by Phase 16
In Progress Trials by Phase 17
Clinical Trials by Trial Status 18
Clinical Trials by End Point Status 19
Subjects Recruited Over a Period of Time 20
Clinical Trials by Sponsor Type 21
Prominent Sponsors 22
Top Companies Participating in Neuroendocrine Carcinoma Therapeutics Clinical Trials 23
Prominent Drugs 24
Clinical Trial Profile Snapshots 25
Appendix 71
Abbreviations 71
Definitions 71
Research Methodology 72
Secondary Research 72
About GlobalData 73
Contact Us 73
Disclaimer 73
Source 74

List of Tables
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials by Region, 2016* 5
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 6
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 7
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2016* 8
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 9
Neuroendocrine Carcinoma Therapeutics Clinical Trials, North America, Top Countries, 2016* 10
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 11
Proportion of Neuroendocrine Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2016* 12
Neuroendocrine Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 13
Neuroendocrine Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 14
Proportion of Neuroendocrine Carcinoma to Oncology Clinical Trials, E7 Countries (%), 2016* 15
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials by Phase, 2016* 16
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 17
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 18
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 19
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 20
Neuroendocrine Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 21
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 22
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 23
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 24

List of Figures
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials by Region (%), 2016* 5
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 6
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 7
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2016* 8
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 9
Neuroendocrine Carcinoma Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 10
Proportion of Neuroendocrine Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2016* 12
Neuroendocrine Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 13
Neuroendocrine Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 14
Proportion of Neuroendocrine Carcinoma to Oncology Clinical Trials, E7 Countries (%), 2016* 15
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials by Phase (%), 2016* 16
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 17
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 18
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 19
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 20
Neuroendocrine Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 21
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 22
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 23
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 24
GlobalData Methodology 72

【掲載企業】

Novartis AG
Pfizer Inc.
Daiichi Sankyo Company, Limited
Celgene Corporation
Bristol-Myers Squibb Company
Barwon Health
Assign Clinical Research GmbH
Andarix Pharmaceuticals, Inc.
Advanced Accelerator Applications SA
AbbVie Inc.

【レポートのキーワード】

神経内分泌がん(Neuroendocrine Carcinoma)、治験、臨床試験、治験、治療薬

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 神経内分泌がん(Neuroendocrine Carcinoma):世界の治験レビュー(2016年上半期版)(Neuroendocrine Carcinoma Global Clinical Trials Review, H1, 2016)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆